Skip to main content
HCPCS Q5111 · Level II · Part B drug

Q5111: pegfilgrastim-cbqv (Udenyca, Udenyca Onbody), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5111

Billing unit
0.5 MG
Injection, udenyca 0.5 mg
ASP payment limit
$128.967
October 2026; -13.5% vs July 2026
Practitioner MUE
12
MAI 3
OPPS status
SI K
APC 9195
NCCI exposure
no PTP pairs
Coverage articles
3
6 states

TL;DR

HCPCS Q5111 is the Level II code for Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg, billed per 0.5 MG. The Medicare Part B ASP payment limit for October 2026 is $128.967 per billing unit, down 13.5% from July 2026. The practitioner MUE allows up to 12 units per date of service (MAI 3), so a full 12-unit day is $1,547.60 at the current limit. Under OPPS it carries status indicator K in APC 9195. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. Other HCPCS codes whose descriptor names pegfilgrastim: Q5108 (biosimilar pegfilgrastim-jmdb (Fulphila)); Q5120 (biosimilar pegfilgrastim-bmez (Ziextenzo) from Sandoz Inc); Q5122 (biosimilar pegfilgrastim-apgf (Nyvepria) from Pfizer Inc); Q5127 (biosimilar pegfilgrastim-fpgk (Stimufend)); Q5130 (biosimilar pegfilgrastim-pbbk (Fylnetra) from Amneal Pharmaceuticals, LLC); Q5169 (biosimilar pegfilgrastim-unne (Armlupeg) from Lupin Pharmaceuticals, Inc). The ASP crosswalk maps 6 NDCs to it, sold as Udenyca, Udenyca Onbody by Accord BioPharma, Inc, Coherus BioSciences, Inc. 3 Medicare coverage articles list the code across 6 states, including A54682.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5111 at $128.967 per 0.5 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $149.133 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q5111
QuarterPayment limitPerCoinsurance
October 2026$128.9670.5 MG20%
July 2026$149.1330.5 MG—
CMS note: AMP-based payment limit

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 6 NDCs from 2 labelers to Q5111. Report the NDC in the claim's drug segment and bill the number of Q5111 units that equals the quantity administered divided by 0.5 MG; the last column gives units per full package.

NDCs that crosswalk to Q5111
NDCDrug nameLabelerPackage sizeBilling units / package
69448-0025-63UdenycaAccord BioPharma, Inc0.6 × 112
69448-0026-63UdenycaAccord BioPharma, Inc0.6 × 112
69448-0027-63Udenyca OnbodyAccord BioPharma, Inc0.6 × 112
70114-0101-01UdenycaCoherus BioSciences, Inc.0.6 × 112
70114-0120-01UdenycaCoherus BioSciences, Inc.0.6 × 112
70114-0130-01UdenycaCoherus BioSciences, Inc.0.6 × 112

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for Q5111. For practitioners the limit is 12 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q5111 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services123 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital123 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for Q5111 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5111 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5111 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5111 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

3 current Medicare Administrative Contractor articles list Q5111 in their HCPCS tables, covering 6 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing Q5111
ArticleTitleContractor(s)StatesRelated LCD
A54682Billing and Coding: Neulasta® (pegfilgrastim) Onpro® Kit / UDENYCA® ONBODY™ (On-body Injector)Palmetto GBANC SC VA WVL37175, L37176
A56748Billing and Coding: White Cell Colony Stimulating FactorsPalmetto GBANC SC VA WVL37176
A59126Pegfilgrastim (Fulphila; Neulasta; Neulasta Onpro; Nyvepria; Udenyca; Ziextenzo) J2506CGS Administrators, LLCKY OH—

Diagnoses Medicare contractors cover for Q5111

One billing and coding article attaches a covered diagnosis list to Q5111: 1,256 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for Q5111
ICD-10-CMDescription (FY2027)Articles covering
C00.0Malignant neoplasm of external upper lip1 of 1
C00.1Malignant neoplasm of external lower lip1 of 1
C00.2Malignant neoplasm of external lip, unspecified1 of 1
C00.3Malignant neoplasm of upper lip, inner aspect1 of 1
C00.4Malignant neoplasm of lower lip, inner aspect1 of 1
C00.5Malignant neoplasm of lip, unspecified, inner aspect1 of 1
C00.6Malignant neoplasm of commissure of lip, unspecified1 of 1
C00.8Malignant neoplasm of overlapping sites of lip1 of 1
C00.9Malignant neoplasm of lip, unspecified1 of 1
C01Malignant neoplasm of base of tongue1 of 1
C02.0Malignant neoplasm of dorsal surface of tongue1 of 1
C02.1Malignant neoplasm of border of tongue1 of 1
C02.2Malignant neoplasm of ventral surface of tongue1 of 1
C02.3Malignant neoplasm of anterior two-thirds of tongue, part unspecified1 of 1
C02.4Malignant neoplasm of lingual tonsil1 of 1
1,241 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q5111 are counted here: a group whose instructions name Q5111, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to Q5111, by article
ArticleContractorGroups that applyCovered codes for Q5111Full list
A54682Palmetto GBAno covered diagnosis list0On LCD L37176
A56748Palmetto GBA6 groups apply to Q51111,256On LCD L37176

Local coverage policies that list Q5111

1 active Local Coverage Determination lists Q5111 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5111 carries status indicator K and is assigned to APC 9195, with a published national unadjusted payment of $128.967. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5111 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $128.97 per 0.5 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5111 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5111

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5111

What does HCPCS code Q5111 describe?

Q5111 is defined by CMS as "Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg". Each billing unit represents 0.5 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5111 a CPT code?

No. Q5111 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as pegfilgrastim-cbqv; CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5111 reports the drug itself in 0.5 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5111 in October 2026?

The ASP-based payment limit is $128.967 per 0.5 MG, with 20% beneficiary coinsurance. The July 2026 limit was $149.133. Commercial payers use their own fee schedules.

How many units of Q5111 can be billed per day?

The practitioner Medically Unlikely Edit is 12 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q5111?

The October 2026 ASP crosswalk lists 6 NDCs from 2 labelers: Udenyca (Accord BioPharma, Inc); Udenyca Onbody (Accord BioPharma, Inc); Udenyca (Coherus BioSciences, Inc.). For example NDC 69448-0025-63 (package size 0.6) equals 12 billing units of Q5111.

Does Q5111 have NCCI bundling edits?

No active practitioner PTP pairs list Q5111 as a column-1 or column-2 code in the v323r0 release.

Q5111 vs Q5108: what is the difference?

Both are HCPCS Level II codes whose descriptor names pegfilgrastim. What sets Q5108 apart: biosimilar pegfilgrastim-jmdb (Fulphila). Q5111 is billed per 0.5 mg, limit $128.967, MUE 12; Q5108 is billed per 0.5 mg, limit $55.964, MUE 12. Report the code whose descriptor matches the product and setting in the record.

Q5111 vs Q5120: what is the difference?

Both are HCPCS Level II codes whose descriptor names pegfilgrastim. What sets Q5120 apart: biosimilar pegfilgrastim-bmez (Ziextenzo) from Sandoz Inc. Q5111 is billed per 0.5 mg, limit $128.967, MUE 12; Q5120 is billed per 0.5 mg, limit $302.247, MUE 12. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention Q5111?

3 current Billing and Coding Articles in the Medicare Coverage Database list Q5111, covering 6 states: A54682 (Billing and Coding: Neulasta® (pegfilgrastim) Onpro® Kit / UDENYCA® ONBODY™ (On-body Injector)); A56748 (Billing and Coding: White Cell Colony Stimulating Factors); A59126 (Pegfilgrastim (Fulphila; Neulasta; Neulasta Onpro; Nyvepria; Udenyca; Ziextenzo) J2506).

What diagnosis codes support Q5111?

One Medicare billing and coding article lists 1,256 covered ICD-10-CM codes for Q5111, for example C00.0 (Malignant neoplasm of external upper lip); C00.1 (Malignant neoplasm of external lower lip); C00.2 (Malignant neoplasm of external lip, unspecified); C00.3 (Malignant neoplasm of upper lip, inner aspect); C00.4 (Malignant neoplasm of lower lip, inner aspect). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.